Apellis Pharmaceuticals (NASDAQ: APLS) has announced that it will be releasing its financial results for the third quarter of 2024 on Tuesday 5th November 2024. The report will be made available before market open, allowing investors and analysts to evaluate the company's performance during this period.
In accordance with the forecasts of financial specialists on Wall Street, the enterprise is primed to announce an anticipated $0.30 loss per share for the quarter. Additionally, the company is projected to reveal a total revenue of $200.35 million for this particular period.
The projections from Wall Street analysts indicate that the company is expected to generate a total revenue of $786.28 million for the full year. Moreover, they anticipate the earnings per share to reach loss of $1.33 during the fiscal year.
Examining the corresponding quarter from the previous year, the company's earnings report unveiled a loss of $1.17 per share. This number was attributed to the company's total revenue, which settled at an impressive $110.4 million during the same period.
APLS will host a conference call with investment community on 5th November 2024 at 08:30 AM eastern time to discuss the financial results.
Apellis Pharmaceuticals (APLS) closed Friday's regular trading session at $27.98, reflecting a 2.64 percent advance. During the day, APLS shares traded between $27.11 and $28.10, with a day volume of 1.22 million shares.
